Home » Stocks » IPCIF

Intellipharmaceutics International Inc. (IPCIF)

Stock Price: $0.2945 USD 0.0045 (1.55%)
Updated Mar 2, 2021 3:47 PM EST - Market closed
Market Cap 5.62M
Revenue (ttm) 3.48M
Net Income (ttm) -8.08M
Shares Out 21.58M
EPS (ttm) -0.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 2
Last Price $0.2945
Previous Close $0.2900
Change ($) 0.0045
Change (%) 1.55%
Day's Open 0.3000
Day's Range 0.2945 - 0.3000
Day's Volume 7,060
52-Week Range 0.0588 - 0.48

News

Hide News
Accesswire - 4 days ago

TORONTO, ON / ACCESSWIRE / March 1, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing...

Accesswire - 2 months ago

TORONTO, ON / ACCESSWIRE / December 23, 2020 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing...

About IPCIF

Intellipharmaceutics International, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hype... [Read more...]

Industry
Biotechnology
Founded
1998
CEO
Isa Odidi
Country
Canada
Stock Exchange
OTCMKTS
Ticker Symbol
IPCIF
Full Company Profile

Financial Performance

In 2019, IPCIF's revenue was $3.48 million, an increase of 103.21% compared to the previous year's $1.71 million. Losses were -$8.08 million, -41.19% less than in 2018.

Financial Statements